NO317801B1 - DNA-molekyl, kimaert DNA-molekyl eller vektor som koder for BMP12 eller BMP12-relaterte proteiner, og vertceller, fremgangsmater, proteiner, sammensetninger og anvendelse derav. - Google Patents

DNA-molekyl, kimaert DNA-molekyl eller vektor som koder for BMP12 eller BMP12-relaterte proteiner, og vertceller, fremgangsmater, proteiner, sammensetninger og anvendelse derav. Download PDF

Info

Publication number: NO317801B1
Authority: NO; Norway
Prior art keywords: bmp; seq; sequence; protein; dna
Prior art date: 1993-12-07

Application number

NO19962304A

Other languages

English (en)

Norwegian (no)

Other versions

NO962304D0 (no

NO962304L (no

Inventor

John M Wozney

Anthony J Celeste

Neil M Wolfman

Vicki A Rosen

Gerald H Thomsen

Douglas A Melton

Original Assignee

Genetics Inst

Harvard College

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-07

Filing date

1996-06-04

Publication date

2004-12-13

1994-11-02 Priority claimed from US08/333,576 external-priority patent/US6027919A/en

1996-06-04 Application filed by Genetics Inst, Harvard College filed Critical Genetics Inst

1996-06-04 Publication of NO962304D0 publication Critical patent/NO962304D0/no

1996-06-04 Publication of NO962304L publication Critical patent/NO962304L/no

2004-12-13 Publication of NO317801B1 publication Critical patent/NO317801B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 258
102000004169 proteins and genes Human genes 0.000 title claims abstract description 238
239000000203 mixture Substances 0.000 title claims abstract description 66
108020004414 DNA Proteins 0.000 title claims description 90
238000000034 method Methods 0.000 title claims description 58
239000013598 vector Substances 0.000 title claims description 34
102000053602 DNA Human genes 0.000 title claims description 18
101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 title description 15
102100035363 Growth/differentiation factor 7 Human genes 0.000 title 2
210000002435 tendon Anatomy 0.000 claims abstract description 102
230000001939 inductive effect Effects 0.000 claims abstract description 37
210000003041 ligament Anatomy 0.000 claims abstract description 29
230000007547 defect Effects 0.000 claims abstract description 13
208000000491 Tendinopathy Diseases 0.000 claims abstract description 7
206010043255 Tendonitis Diseases 0.000 claims abstract description 7
201000004415 tendinitis Diseases 0.000 claims abstract description 7
239000002773 nucleotide Substances 0.000 claims description 144
125000003729 nucleotide group Chemical group 0.000 claims description 144
108091028043 Nucleic acid sequence Proteins 0.000 claims description 115
125000003275 alpha amino acid group Chemical group 0.000 claims description 76
210000001519 tissue Anatomy 0.000 claims description 72
150000001413 amino acids Chemical class 0.000 claims description 62
108090000765 processed proteins & peptides Proteins 0.000 claims description 51
230000014509 gene expression Effects 0.000 claims description 35
229920001184 polypeptide Polymers 0.000 claims description 34
102000004196 processed proteins & peptides Human genes 0.000 claims description 34
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 33
108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 19
102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 19
230000015572 biosynthetic process Effects 0.000 claims description 19
210000000988 bone and bone Anatomy 0.000 claims description 16
230000009772 tissue formation Effects 0.000 claims description 16
238000009396 hybridization Methods 0.000 claims description 14
108020004705 Codon Proteins 0.000 claims description 13
230000000295 complement effect Effects 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
239000000178 monomer Substances 0.000 claims description 10
239000001963 growth medium Substances 0.000 claims description 9
238000012258 culturing Methods 0.000 claims description 7
239000000539 dimer Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 5
238000002955 isolation Methods 0.000 claims description 5
230000000921 morphogenic effect Effects 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000000746 purification Methods 0.000 claims description 3
230000017423 tissue regeneration Effects 0.000 abstract description 10
235000018102 proteins Nutrition 0.000 description 223
235000001014 amino acid Nutrition 0.000 description 65
229940024606 amino acid Drugs 0.000 description 62
210000004027 cell Anatomy 0.000 description 60
108091034117 Oligonucleotide Proteins 0.000 description 53
239000012634 fragment Substances 0.000 description 43
108091026890 Coding region Proteins 0.000 description 33
241001529936 Murinae Species 0.000 description 33
239000013615 primer Substances 0.000 description 29
230000003321 amplification Effects 0.000 description 27
238000003199 nucleic acid amplification method Methods 0.000 description 27
239000002299 complementary DNA Substances 0.000 description 22
108091008146 restriction endonucleases Proteins 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 20
239000013612 plasmid Substances 0.000 description 20
239000000047 product Substances 0.000 description 18
101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 16
239000000872 buffer Substances 0.000 description 14
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 14
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 14
241000894007 species Species 0.000 description 14
241000588724 Escherichia coli Species 0.000 description 13
102000048885 human GDF7 Human genes 0.000 description 13
210000004962 mammalian cell Anatomy 0.000 description 13
241001515965 unidentified phage Species 0.000 description 13
101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 12
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
230000001580 bacterial effect Effects 0.000 description 12
-1 poly(lactic acid) Polymers 0.000 description 12
101000851110 Periplaneta americana Vitellogenin-1 Proteins 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
108020005187 Oligonucleotide Probes Proteins 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 10
239000007943 implant Substances 0.000 description 10
239000002751 oligonucleotide probe Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
230000008439 repair process Effects 0.000 description 10
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
239000003155 DNA primer Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108010022394 Threonine synthase Proteins 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
102000004419 dihydrofolate reductase Human genes 0.000 description 9
230000004927 fusion Effects 0.000 description 9
230000013595 glycosylation Effects 0.000 description 9
238000006206 glycosylation reaction Methods 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000007017 scission Effects 0.000 description 9
241000700159 Rattus Species 0.000 description 8
239000000499 gel Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
230000036961 partial effect Effects 0.000 description 8
239000002243 precursor Substances 0.000 description 8
239000000523 sample Substances 0.000 description 8
241000701161 unidentified adenovirus Species 0.000 description 8
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
239000007983 Tris buffer Substances 0.000 description 7
206010052428 Wound Diseases 0.000 description 7
208000027418 Wounds and injury Diseases 0.000 description 7
238000003556 assay Methods 0.000 description 7
229940104302 cytosine Drugs 0.000 description 7
210000003000 inclusion body Anatomy 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
239000003352 sequestering agent Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000002126 C01EB10 - Adenosine Substances 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
239000000020 Nitrocellulose Substances 0.000 description 6
229960005305 adenosine Drugs 0.000 description 6
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
229960000723 ampicillin Drugs 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
235000018417 cysteine Nutrition 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
239000013600 plasmid vector Substances 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 5
102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 5
108020003215 DNA Probes Proteins 0.000 description 5
239000003298 DNA probe Substances 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
108700026244 Open Reading Frames Proteins 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
230000012010 growth Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
230000035876 healing Effects 0.000 description 5
102000045896 human BMP2 Human genes 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
229940113082 thymine Drugs 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 4
102100032352 Leukemia inhibitory factor Human genes 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
239000000356 contaminant Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000009795 derivation Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
244000005700 microbiome Species 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000013519 translation Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 3
108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 3
102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 3
101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 3
102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 3
102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000008033 biological extinction Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
210000000845 cartilage Anatomy 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000010276 construction Methods 0.000 description 3
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
229940126864 fibroblast growth factor Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000000833 heterodimer Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
235000019515 salmon Nutrition 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000008467 tissue growth Effects 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
108010059616 Activins Proteins 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
108010076804 DNA Restriction Enzymes Proteins 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
102000003969 Fibroblast growth factor 4 Human genes 0.000 description 2
108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 2
102100040892 Growth/differentiation factor 2 Human genes 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007997 Tricine buffer Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000000488 activin Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
229920013820 alkyl cellulose Polymers 0.000 description 2
101150114167 ampC gene Proteins 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
230000022159 cartilage development Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000012869 ethanol precipitation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
108010067479 inhibin B Proteins 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
230000006576 neuronal survival Effects 0.000 description 2
230000011164 ossification Effects 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000005382 thermal cycling Methods 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
YZKZXTBSUSEYQZ-UHFFFAOYSA-N 1-[(4-ethoxy-3-methoxyphenyl)methyl]-6,7-dimethoxy-3-methylisoquinoline;phosphoric acid Chemical compound OP(O)(O)=O.C1=C(OC)C(OCC)=CC=C1CC1=NC(C)=CC2=CC(OC)=C(OC)C=C12 YZKZXTBSUSEYQZ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000836430 Hilda Species 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
RCFDOSNHHZGBOY-ACZMJKKPSA-N Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(O)=O RCFDOSNHHZGBOY-ACZMJKKPSA-N 0.000 description 1
102100026818 Inhibin beta E chain Human genes 0.000 description 1
RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
206010061223 Ligament injury Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
101000892448 Neisseria gonorrhoeae Type II restriction enzyme NgoMIV Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000702208 Shigella phage SfX Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000021945 Tendon injury Diseases 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
NZCPCJCJZHKFGZ-AAEUAGOBSA-N Trp-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 NZCPCJCJZHKFGZ-AAEUAGOBSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
101150090507 lacM gene Proteins 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000013289 male long evans rat Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/386—Ligaments, tendons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Rehabilitation Therapy (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
Botany (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)

NO19962304A 1993-12-07 1996-06-04 DNA-molekyl, kimaert DNA-molekyl eller vektor som koder for BMP12 eller BMP12-relaterte proteiner, og vertceller, fremgangsmater, proteiner, sammensetninger og anvendelse derav. NO317801B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US16410393A	1993-12-07	1993-12-07
US21778094A	1994-03-25	1994-03-25
US08/333,576 US6027919A (en)	1993-12-07	1994-11-02	BMP-12 and BMP-13 proteins and DNA encoding them
PCT/US1994/014030 WO1995016035A2 (en)	1993-12-07	1994-12-06	Bmp-12, bmp-13 and tendon-inducing compositions thereof

Publications (3)

Publication Number	Publication Date
NO962304D0 NO962304D0 (no)	1996-06-04
NO962304L NO962304L (no)	1996-06-04
NO317801B1 true NO317801B1 (no)	2004-12-13

Family

ID=27388970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19962304A NO317801B1 (no)	1993-12-07	1996-06-04	DNA-molekyl, kimaert DNA-molekyl eller vektor som koder for BMP12 eller BMP12-relaterte proteiner, og vertceller, fremgangsmater, proteiner, sammensetninger og anvendelse derav.

Country Status (15)

Country	Link
US (5)	US5658882A (de)
EP (1)	EP0733109B9 (de)
JP (3)	JP3717930B2 (de)
KR (1)	KR100353182B1 (de)
AT (1)	ATE319823T1 (de)
AU (1)	AU689184B2 (de)
CA (1)	CA2176942C (de)
DE (1)	DE69434651T2 (de)
DK (1)	DK0733109T3 (de)
ES (1)	ES2255059T3 (de)
FI (1)	FI119816B (de)
NO (1)	NO317801B1 (de)
OA (1)	OA10582A (de)
PT (1)	PT733109E (de)
WO (1)	WO1995016035A2 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en) *	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
US6586388B2 (en)	1988-04-08	2003-07-01	Stryker Corporation	Method of using recombinant osteogenic protein to repair bone or cartilage defects
US20070166353A1 (en) *	1988-04-08	2007-07-19	Stryker Corporation	Osteogenic proteins
US20080139474A1 (en) *	1991-11-04	2008-06-12	David Israel	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
JP3504263B2 (ja)	1991-11-04	2004-03-08	ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー	組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
DE19525416A1 (de) *	1995-07-12	1997-01-16	Bioph Biotech Entw Pharm Gmbh	Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
US20080233170A1 (en) *	1992-02-21	2008-09-25	Stryker Corporation	Osteogenic Proteins
US5770444A (en) *	1993-07-09	1998-06-23	The Johns Hopkins University School Of Medicine	Growth differentiation factor-6
WO1995001802A1 (en) *	1993-07-09	1995-01-19	The Johns Hopkins University School Of Medicine	Growth differentiation factor-7
US6291206B1 (en) *	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
ATE319823T1 (de) *	1993-12-07	2006-03-15	Inst Genetics Llc	Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
US5942496A (en)	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en)	1994-03-15	2003-04-22	University Of Birmingham	Compositions and methods for delivery of agents for neuronal regeneration and survival
US5906827A (en) *	1994-06-03	1999-05-25	Creative Biomolecules, Inc.	Matrix for the manufacture of autogenous replacement body parts
WO1996014335A1 (en) *	1994-11-07	1996-05-17	The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services	Cartilage-derived morphogenetic proteins
US20010011131A1 (en) *	1997-07-28	2001-08-02	Luyten Frank P.	DNA molecules encoding cartilage-derived morphogenetic proteins
US5846770A (en) *	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
BR9608019A (pt) *	1995-04-19	1999-11-30	Hoechst Japan	Uma nova proteína e um processo para a preparação da mesma'
HU222664B1 (hu) *	1995-06-05	2003-09-29	Genetics Institute, Llc	Csont morfogenetikus protein (BMP) alkalmazása csont és ín vagy szalag funkcionális összeköttetésének regenerálására
US5902785A (en) *	1995-06-06	1999-05-11	Genetics Institute, Inc.	Cartilage induction by bone morphogenetic proteins
ZA966489B (en) *	1995-08-03	1997-02-26	Bioph Biotech Entw Pharm Gmbh	New protein human MP52 Arg.
US7026292B1 (en)	1995-12-12	2006-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
DE19548476A1 (de) *	1995-12-22	1997-06-26	Bioph Biotech Entw Pharm Gmbh	Zielgerichtete Verbindungen mit knorpel- und/oder knocheninduzierender Aktivität
US5700774A (en) *	1996-03-26	1997-12-23	Genetics Institute, Inc.	Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US5965403A (en)	1996-09-18	1999-10-12	Genetics Institute, Inc.	Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
EP1074620A1 (de)	1999-08-06	2001-02-07	HyGene AG	Monomer Protein der TGF-beta Familie
JPH11335398A (ja) *	1998-05-22	1999-12-07	Hoechst Marion Roussel Kk	新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
DE69814352T3 (de)	1997-02-07	2009-08-13	Stryker Corp., Kalamazoo	Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung
US7041641B2 (en)	1997-03-20	2006-05-09	Stryker Corporation	Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US20010016646A1 (en)	1998-03-20	2001-08-23	David C. Rueger	Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
AU742613B2 (en) *	1997-04-04	2002-01-10	Barnes-Jewish Hospital	Neocartilage and methods of use
EP1988395A1 (de)	1997-05-30	2008-11-05	Curis, Inc.	Verfahren zur Beurteilung von Gewebemorphogenese und- aktivität
EP0896825B1 (de)	1997-08-14	2002-07-17	Sulzer Innotec Ag	Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6482584B1 (en)	1998-11-13	2002-11-19	Regeneration Technologies, Inc.	Cyclic implant perfusion cleaning and passivation process
US20010031254A1 (en) *	1998-11-13	2001-10-18	Bianchi John R.	Assembled implant
US6281175B1 (en)	1997-09-23	2001-08-28	Scimed Life Systems, Inc.	Medical emulsion for lubrication and delivery of drugs
US20020052026A1 (en)	1997-10-08	2002-05-02	Steven M. Vicik	Methods of refolding proteins
EP1034269A1 (de)	1997-11-28	2000-09-13	Roche Diagnostics GmbH	Aktive hedgehog-protein-mutante, verfahren zur herstellung und verwendung als arzneimittel
US6027917A (en) *	1997-12-10	2000-02-22	Genetics Institute, Inc.	Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
JP4532733B2 (ja)	1998-03-17	2010-08-25	ジェネンテック，インコーポレイテッド	Ｖｅｇｆおよびｂｍｐ１と相同なポリペプチド群
US6294655B1 (en)	1998-04-03	2001-09-25	Hyseq, Inc.	Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6426191B1 (en)	1998-04-03	2002-07-30	Hyseq, Inc.	Assays involving an IL-1 receptor antagonist
US6541623B1 (en)	1998-04-03	2003-04-01	Hyseq, Inc.	Interleukin—1 receptor antagonist and uses thereof
US6337072B1 (en)	1998-04-03	2002-01-08	Hyseq, Inc.	Interleukin-1 receptor antagonist and recombinant production thereof
US7572440B2 (en)	1999-07-30	2009-08-11	Stryker Corporation	Method for repairing a defect in an intervertebral disc
JP4768125B2 (ja) *	1998-10-06	2011-09-07	ラッシュプレスバイテリアンセントルークスメディカルセンター	化学的髄核分解の治療方法
US6958149B2 (en)	1998-10-06	2005-10-25	Stryker Corporation	Repair of larynx, trachea, and other fibrocartilaginous tissues
EP1649865B1 (de) *	1998-10-06	2012-06-13	Stryker Corporation	GDF-5 zur Verwendung für das Reparieren eines nicht-artikulären Knorpelgewebedefekts in einer Bandscheibe
EP1117805A2 (de)	1998-10-07	2001-07-25	STRYKER CORPORATION (a Michigan corporation)	Modifizierte proteine der tgf-beta superfamilie
US6846906B1 (en)	1998-10-07	2005-01-25	Stryker Corporation	Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6677432B1 (en)	1998-10-07	2004-01-13	Stryker Corporation	Mutations of the C-terminal portion of TGF-β superfamily proteins
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
HUP0105312A3 (en) *	1999-02-01	2003-12-29	Genetics Inst Llc Cambridge	Methods and compositions for healing and repair of articular cartilage
ES2295026T3 (es)	1999-04-28	2008-04-16	Genetics Institute, Llc	Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
EP2067788B1 (de)	1999-05-18	2015-07-22	Dyax Corp.	FAB-Fragmentbibliotheken und Verwendungsverfahren dafür
ATE271886T1 (de) *	1999-10-15	2004-08-15	Inst Genetics Llc	Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US6368787B1 (en)	1999-12-16	2002-04-09	Stryker Corporation	Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
WO2001054748A1 (en) *	2000-01-25	2001-08-02	Edwards Lifesciences Corporation	Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
WO2001066130A1 (en) *	2000-03-09	2001-09-13	Sulzer Biologics Inc.	Product and method for biological anchoring of connective tissue to bone
US20030065140A1 (en) *	2000-04-03	2003-04-03	Vernet Corine A.M.	Novel proteins and nucleic acids encoding same
CA2648051A1 (en)	2000-06-23	2002-01-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da)	2000-06-23	2014-08-11	Genentech Inc	Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
US7270730B2 (en) *	2000-08-04	2007-09-18	Essen Instruments, Inc.	High-throughput electrophysiological measurement system
US7067046B2 (en)	2000-08-04	2006-06-27	Essen Instruments, Inc.	System for rapid chemical activation in high-throughput electrophysiological measurements
US20040010118A1 (en) *	2000-08-16	2004-01-15	Zerhusen Bryan D.	Novel proteins and nucleic acids encoding same
US20030082233A1 (en) *	2000-12-01	2003-05-01	Lyons Karen M.	Method and composition for modulating bone growth
WO2002076494A2 (en) *	2001-03-23	2002-10-03	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
JP2005500280A (ja) *	2001-06-01	2005-01-06	ワイエス	骨形成タンパク質（ｂｍｐ）をコードする配列の全身投与のための組成物および方法
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
US20030087274A1 (en) *	2001-07-05	2003-05-08	Anderson David W.	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US8546334B2 (en)	2001-11-19	2013-10-01	Scil Technology Gmbh	Device having osteoinductive and osteoconductive properties
CH695985A5 (de) *	2002-01-21	2006-11-15	Straumann Holding Ag	Oberflächenmodifizierte Implantate.
CN1665525A (zh) *	2002-05-17	2005-09-07	惠氏公司	用于递送骨生成蛋白质的可注入固体透明质酸载体
US7622562B2 (en)	2002-06-26	2009-11-24	Zimmer Orthobiologics, Inc.	Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
CN1735426A (zh)	2002-08-13	2006-02-15	惠氏公司	用作转化生长因子β蛋白质的溶解赋形剂的肽
AU2003253049A1 (en)	2002-09-10	2004-04-30	Scil Technology Gmbh	Metal implant coated under reduced oxygen concentration with osteoinductive protein
WO2005012530A2 (en)	2003-07-25	2005-02-10	Amgen Inc.	Antagonists and agonists of ldcam and methods of use
DE602004005477T2 (de)	2003-09-12	2007-12-13	Wyeth	Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
CA2535169A1 (en) *	2003-12-31	2005-07-21	Osteotech, Inc.	Improved bone matrix compositions and methods
US7767221B2 (en) *	2004-03-05	2010-08-03	The Trustees Of Columbia University In The City Of New York	Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone
CA2558395C (en)	2004-03-10	2011-11-29	Scil Technology Gmbh	Coated implants, their manufacturing and use thereof
EP1740609A2 (de)	2004-04-27	2007-01-10	Research Development Foundation	Antagonismus des tgf-beta superfamily signal rezeptors
JP5201987B2 (ja)	2004-05-25	2013-06-05	ストライカーコーポレイション	軟骨欠損を処置するための、形態形成タンパク質の使用
WO2006026731A1 (en)	2004-08-30	2006-03-09	Spineovations, Inc.	Method of treating spinal internal disk derangement
AU2005279960A1 (en) *	2004-08-30	2006-03-09	Neville Alleyne	Method of using an implant for treatment of ligaments and tendons
US7473678B2 (en)	2004-10-14	2009-01-06	Biomimetic Therapeutics, Inc.	Platelet-derived growth factor compositions and methods of use thereof
US20060166251A1 (en) *	2005-01-26	2006-07-27	Archambault Joanne M	Use of sFRPs as markers of BMP activity
US20070111937A1 (en) *	2005-03-24	2007-05-17	Pickar James H	Use of fibrous tissue inducing proteins for hernia repair
JP2008534607A (ja) *	2005-03-30	2008-08-28	ワイス	Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
US20060247790A1 (en) *	2005-04-30	2006-11-02	Mckay William F	Shaped osteochondral grafts and methods of using same
US20060287676A1 (en) *	2005-06-15	2006-12-21	Rita Prajapati	Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060286289A1 (en) *	2005-06-15	2006-12-21	Rita Prajapati	Method of intraoperative coating therapeutic agents onto sutures
US20060287675A1 (en) *	2005-06-15	2006-12-21	Prajapati Rita T	Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use
US20060286171A1 (en) *	2005-06-17	2006-12-21	Tianhong Zhou	Bone morphogenetic protein formulations
WO2007052096A2 (en) *	2005-06-29	2007-05-10	Cameron Malcolm Lang Clokie	Production of bone morphogenic proteins (bmps) in transgenic mammals
US8911759B2 (en)	2005-11-01	2014-12-16	Warsaw Orthopedic, Inc.	Bone matrix compositions and methods
PL1948689T3 (pl) *	2005-11-18	2012-09-28	Biopharm Ges Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Mutanty czynników wzrostu o wysokiej aktywności
US8147860B2 (en)	2005-12-06	2012-04-03	Etex Corporation	Porous calcium phosphate bone material
WO2007092622A2 (en)	2006-02-09	2007-08-16	Biomimetic Therapeutics, Inc.	Compositions and methods for treating bone
JP5362554B2 (ja)	2006-05-17	2013-12-11	ストライカーコーポレイション	軟骨の欠損を処置するための可溶性形態形成タンパク質の使用
US9161967B2 (en)	2006-06-30	2015-10-20	Biomimetic Therapeutics, Llc	Compositions and methods for treating the vertebral column
CA2656278C (en)	2006-06-30	2016-02-09	Biomimetic Therapeutics, Inc.	Compositions and methods for treating rotator cuff injuries
US8524265B2 (en)	2006-08-17	2013-09-03	Warsaw Orthopedic, Inc.	Medical implant sheets useful for tissue regeneration
US20100047309A1 (en) *	2006-12-06	2010-02-25	Lu Helen H	Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods
AU2007234612B2 (en)	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
JP5452230B2 (ja)	2006-12-21	2014-03-26	ストライカーコーポレイション	生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物
US8753391B2 (en)	2007-02-12	2014-06-17	The Trustees Of Columbia University In The City Of New York	Fully synthetic implantable multi-phased scaffold
WO2008144900A1 (en) *	2007-05-25	2008-12-04	Peel Sean A	A method of enhancing recombinant protein production
US20080299172A1 (en) *	2007-06-04	2008-12-04	Stuart Young	Tissue repair implant
US9554920B2 (en)	2007-06-15	2017-01-31	Warsaw Orthopedic, Inc.	Bone matrix compositions having nanoscale textured surfaces
CA3062443C (en)	2007-06-15	2022-03-15	Warsaw Orthopedic, Inc.	Method of treating tissue
WO2008157492A2 (en)	2007-06-15	2008-12-24	Osteotech, Inc.	Osteoinductive demineralized cancellous bone
CA2690457C (en)	2007-06-15	2018-02-20	Osteotech, Inc.	Bone matrix compositions and methods
US7678764B2 (en)	2007-06-29	2010-03-16	Johnson & Johnson Regenerative Therapeutics, Llc	Protein formulations for use at elevated temperatures
WO2009009688A1 (en)	2007-07-10	2009-01-15	Osteotech, Inc.	Delivery system
EP2019117A1 (de) *	2007-07-27	2009-01-28	BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH	Optimiertes Reinigungsverfahren für rekombinantes Wachstumsfaktorprotein
CN101801405A (zh)	2007-08-07	2010-08-11	先进科技及再生医学有限责任公司	包含于酸性水溶液中的gdf-5的蛋白质配方
US8202539B2 (en) *	2007-10-19	2012-06-19	Warsaw Orthopedic, Inc.	Demineralized bone matrix compositions and methods
US8741840B2 (en)	2008-02-13	2014-06-03	Washington University	BMP-7 for use in treating neointimal hyperplasia
US8469961B2 (en) *	2008-03-05	2013-06-25	Neville Alleyne	Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US20100004700A1 (en) *	2008-03-05	2010-01-07	Neville Alleyne	Method of treating tissue with a suspenson of tricalcium hydroxyapatite microspheres
US20100010549A1 (en) *	2008-03-05	2010-01-14	Neville Alleyne	device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries
BRPI0911048A2 (pt)	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
JP2011522565A (ja) *	2008-06-09	2011-08-04	ワイス・エルエルシー	新規ｂｍｐ−１２関連タンパク質およびその製造方法
AU2009291828C1 (en)	2008-09-09	2016-03-17	Biomimetic Therapeutics, Llc	Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
SG173634A1 (en)	2009-02-12	2011-09-29	Stryker Corp	COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
WO2010093955A1 (en)	2009-02-12	2010-08-19	Osteotech,Inc.	Segmented delivery system
SG2014010680A (en)	2009-02-12	2014-04-28	Stryker Corp	Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
US20120148539A1 (en)	2009-03-24	2012-06-14	Moulay Hicham Alaoui-Ismaili	Methods and Compositions for Tissue Engineering
US8609127B2 (en)	2009-04-03	2013-12-17	Warsaw Orthopedic, Inc.	Medical implant with bioactive material and method of making the medical implant
US20110002897A1 (en)	2009-06-11	2011-01-06	Burnham Institute For Medical Research	Directed differentiation of stem cells
US20110224138A1 (en)	2009-09-09	2011-09-15	Julie Krop	Methods for treating pain induced by injuries and diseases of an articular joint
CA2774024A1 (en)	2009-09-17	2011-03-24	Stryker Corporation	Buffers for controlling the ph of bone morphogenetic proteins
US8657859B2 (en)	2009-12-16	2014-02-25	Advanced Veterinary Solutions	Implant for promoting stability of the canine stifle joint
AU2010341565A1 (en)	2009-12-22	2012-07-12	Stryker Corporation	BMP-7 variants with reduced immunogenicity
EP2538791B1 (de)	2010-02-22	2015-04-08	BioMimetic Therapeutics, LLC	Wachtstumsfaktorzusammensetzungen aus thrombozyten und verfahren zur behandlung von tendinopathie
JP5837930B2 (ja)	2010-07-30	2015-12-24	ビオファーム・ゲゼルシャフト・ツァ・ビオテヒノロジッシェン・エントヴィックルング・フォン・ファルマカ・エムベーハー	創傷の治癒を加速する医薬送達装置及び増殖因子製剤
EP2537538A1 (de)	2011-06-22	2012-12-26	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH	Bioresorbierbarer Wundverband
EP2602264A1 (de)	2011-12-05	2013-06-12	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH	GDF-5-Mutant zur Induzierung der Knorpelbildung
WO2014012101A1 (en)	2012-07-13	2014-01-16	Trustees Of Tufts College	Silk powder compaction for production of constructs with high mechanical strength and stiffness
WO2014169249A1 (en)	2013-04-12	2014-10-16	The Trustees Of Columbia University In The City Of New York	Methods for host cell homing and dental pulp regeneration
KR102024447B1 (ko)	2015-01-16	2019-11-14	스파인오베이션즈, 인크.	척추 디스크를 치료하기 위한 작용제 및 작용제를 포함하는 의료 키트
WO2017075055A1 (en)	2015-10-26	2017-05-04	President And Fellows Of Harvard College	Reduced and oxidized polysaccharides and methods of use thereof
KR101659796B1 (ko)	2016-01-13	2016-10-10	주식회사 셀루메드	특정 비의 bmp 단백질 혼합물
US20190328792A1 (en) *	2017-01-11	2019-10-31	Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung	Mesenchymal stem cell-derived extracellular vesicles and their medical use
WO2021122545A1 (en)	2019-12-18	2021-06-24	Merck Patent Gmbh	Use of the gdf-5 mutant for the treatment of pain and cartilage destruction

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2465357A (en)	1944-08-14	1949-03-29	Upjohn Co	Therapeutic sponge and method of making
CH563767A5 (de)	1973-01-30	1975-07-15	Pheulpin Jean
US4468464A (en)	1974-11-04	1984-08-28	The Board Of Trustees Of The Leland Stanford Junior University	Biologically functional molecular chimeras
DE2657370C2 (de)	1976-12-17	1982-11-11	Hans Dr.med. Dr.med.dent. 8000 München Scheicher	Mittel zum Bedecken und/oder Ausfüllen von Knochendefekten
DE2732848A1 (de)	1977-07-18	1979-02-08	Schering Ag	Diurethane, herbizide mittel enthaltend diese verbindungen sowie verfahren zu ihrer herstellung
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4619989A (en)	1981-05-05	1986-10-28	The Regents Of The University Of Cal.	Bone morphogenetic protein composition
US4789732A (en)	1980-08-04	1988-12-06	Regents Of The University Of California	Bone morphogenetic protein composition
US4294753A (en) *	1980-08-04	1981-10-13	The Regents Of The University Of California	Bone morphogenetic protein process
US4761471A (en) *	1980-08-04	1988-08-02	The Regents Of The University Of California	Bone morphogenetic protein composition
US4455256A (en)	1981-05-05	1984-06-19	The Regents Of The University Of California	Bone morphogenetic protein
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4727028A (en)	1981-06-22	1988-02-23	Eli Lilly And Company	Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4472840A (en)	1981-09-21	1984-09-25	Jefferies Steven R	Method of inducing osseous formation by implanting bone graft material
US4394370A (en)	1981-09-21	1983-07-19	Jefferies Steven R	Bone graft material for osseous defects and method of making same
US4474181A (en)	1982-02-18	1984-10-02	Schenck Robert R	Method and apparatus for anastomosing small blood vessels
US4455526A (en) *	1982-06-29	1984-06-19	The United States Of America As Represented By The Secretary Of The Air Force	FET Switching regulator
EP0105014B1 (de)	1982-09-24	1992-05-20	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Wiederherstellung von Gewebe bei Tieren
IL68218A (en)	1983-03-23	1985-12-31	Univ Ramot	Compositions for cartilage repair comprising embryonal chondrocytes
US4434094A (en) *	1983-04-12	1984-02-28	Collagen Corporation	Partially purified osteogenic factor and process for preparing same from demineralized bone
US4795804A (en)	1983-08-16	1989-01-03	The Regents Of The University Of California	Bone morphogenetic agents
US4923805A (en)	1983-11-02	1990-05-08	Integrated Genetics, Inc.	Fsh
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
GB8334498D0 (en)	1983-12-24	1984-02-01	Beecham Group Plc	Compounds
US4804744A (en) *	1984-01-04	1989-02-14	International Genetic Engineering, Inc.	Osteogenic factors
US4608199A (en)	1984-03-20	1986-08-26	Arnold Caplan	Bone protein purification process
US4662884A (en)	1984-04-25	1987-05-05	University Of Utah Research Foundation	Prostheses and methods for promoting nerve regeneration
US4596574A (en)	1984-05-14	1986-06-24	The Regents Of The University Of California	Biodegradable porous ceramic delivery system for bone morphogenetic protein
CA1341617C (en)	1984-06-08	2011-06-28	Henry George Burger	Inhibin isolated from ovarian follicular fluid
US4868161A (en)	1984-06-29	1989-09-19	City Of Hope	Method for promoting nerve regeneration
ATE128715T1 (de) *	1984-07-16	1995-10-15	Celtrix Pharma	Polypeptide induzierende faktoren in knochen und knorpel.
US4627982A (en) *	1984-07-16	1986-12-09	Collagen Corporation	Partially purified bone-inducing factor
US4843063A (en)	1984-07-16	1989-06-27	Collagen Corporation	Polypeptide cartilage-inducing factors found in bone
EP0177343B1 (de)	1984-10-05	1992-07-22	Genentech, Inc.	DNA, Zellkulturen und Verfahren zur Sekretion von heterologen Proteinen und periplasmische Proteinrückgewinnung
US5187263A (en)	1984-10-12	1993-02-16	Zymogenetics, Inc.	Expression of biologically active PDGE analogs in eucaryotic cells
US4769328A (en)	1984-10-12	1988-09-06	Zymogenetics Inc.	Expression of biologically active PDGF analogs in yeast
US4563350A (en) *	1984-10-24	1986-01-07	Collagen Corporation	Inductive collagen based bone repair preparations
AU598455B2 (en)	1984-12-27	1990-06-28	Suntory Limited	Method for purifying an interferon
US4886747A (en)	1985-03-22	1989-12-12	Genentech, Inc.	Nucleic acid encoding TGF-β and its uses
US4766067A (en)	1985-05-31	1988-08-23	President And Fellows Of Harvard College	Gene amplification
US4681763A (en)	1985-06-11	1987-07-21	University Of Medicine And Dentistry Of New Jersey	Composition for stimulating bone growth
US4851521A (en)	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
US5089396A (en)	1985-10-03	1992-02-18	Genentech, Inc.	Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4798885A (en)	1986-02-07	1989-01-17	Genentech, Inc.	Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5215893A (en)	1985-10-03	1993-06-01	Genentech, Inc.	Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en)	1986-02-10	1988-04-12	The Salk Institute For Biological Studies	Human inhibin
US4758233A (en)	1986-04-22	1988-07-19	N.J. Phillips TPY. Limited	Cream applicator
NL8601328A (nl)	1986-05-23	1987-12-16	Langen Research	Inrichting voor het met een massa, in het bijzonder pasteuze massa, injekteren van vlees.
US5013649A (en) *	1986-07-01	1991-05-07	Genetics Institute, Inc.	DNA sequences encoding osteoinductive products
US5631142A (en) *	1986-07-01	1997-05-20	Genetics Institute, Inc.	Compositions comprising bone morphogenetic protein-2 (BMP-2)
US5187076A (en) *	1986-07-01	1993-02-16	Genetics Institute, Inc.	DNA sequences encoding BMP-6 proteins
ZA874681B (en) *	1986-07-01	1988-04-27	Genetics Inst	Novel osteoinductive factors
US4877864A (en) *	1987-03-26	1989-10-31	Genetics Institute, Inc.	Osteoinductive factors
US5106748A (en) *	1986-07-01	1992-04-21	Genetics Institute, Inc.	Dna sequences encoding 5 proteins
US6150328A (en) *	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
US6432919B1 (en) *	1986-07-01	2002-08-13	Genetics Institute, Inc.	Bone morphogenetic protein-3 and compositions
US5543394A (en) *	1986-07-01	1996-08-06	Genetics Institute, Inc.	Bone morphogenetic protein 5(BMP-5) compositions
US5459047A (en) *	1986-07-01	1995-10-17	Genetics Institute, Inc.	BMP-6 proteins
US5108922A (en) *	1986-07-01	1992-04-28	Genetics Institute, Inc.	DNA sequences encoding BMP-1 products
US5019087A (en)	1986-10-06	1991-05-28	American Biomaterials Corporation	Nerve regeneration conduit
US5124316A (en)	1986-11-14	1992-06-23	President And Fellows Of Harvard College	Method for periodontal regeneration
US5041538A (en)	1987-08-28	1991-08-20	The Salk Institute For Biological Studies	Mammalian follistatin
US5202120A (en)	1987-09-11	1993-04-13	Case Western Reserve University	Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5147399A (en)	1988-02-01	1992-09-15	Dellon Arnold L	Method of treating nerve defects through use of a bioabsorbable surgical device
EP0336760A3 (de) *	1988-04-06	1991-03-13	Celtrix Pharmaceuticals, Inc.	Knochenwachstum induzierendes Protein
US4968590A (en) *	1988-04-08	1990-11-06	Stryker Corporation	Osteogenic proteins and polypeptides
US5354557A (en)	1988-04-08	1994-10-11	Stryker Corporation	Osteogenic devices
US5011691A (en)	1988-08-15	1991-04-30	Stryker Corporation	Osteogenic devices
US5266683A (en)	1988-04-08	1993-11-30	Stryker Corporation	Osteogenic proteins
US5108753A (en)	1988-04-08	1992-04-28	Creative Biomolecules	Osteogenic devices
US6586388B2 (en) *	1988-04-08	2003-07-01	Stryker Corporation	Method of using recombinant osteogenic protein to repair bone or cartilage defects
US5258494A (en) *	1988-04-08	1993-11-02	Stryker Corporation	Osteogenic proteins
US5024841A (en)	1988-06-30	1991-06-18	Collagen Corporation	Collagen wound healing matrices and process for their production
US5071834A (en)	1988-09-16	1991-12-10	Genentech, Inc.	Purified activin B composition
US5106626A (en)	1988-10-11	1992-04-21	International Genetic Engineering, Inc.	Osteogenic factors
US5284756A (en) *	1988-10-11	1994-02-08	Lynn Grinna	Heterodimeric osteogenic factor
US4955892A (en)	1988-10-24	1990-09-11	Louisiana State University	Neural cell adhesion protein nerve prosthesis
US5457038A (en) *	1988-11-10	1995-10-10	Genetics Institute, Inc.	Natural killer stimulatory factor
US5011486A (en)	1988-11-18	1991-04-30	Brown University Research Foundation	Composite nerve guidance channels
US5162430A (en)	1988-11-21	1992-11-10	Collagen Corporation	Collagen-polymer conjugates
US4920962A (en)	1988-11-23	1990-05-01	Claude Proulx	Splint-like element for use in end-to-end nerve suture
US5217867A (en)	1988-11-30	1993-06-08	The Salk Institute For Biological Studies	Receptors: their identification, characterization, preparation and use
US5026381A (en)	1989-04-20	1991-06-25	Colla-Tec, Incorporated	Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit
US4963146A (en)	1989-04-20	1990-10-16	Colla-Tec Incorporated	Multi-layered, semi-permeable conduit for nerve regeneration
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
CA2017466A1 (en) *	1989-06-02	1990-12-02	Michael C. Kiefer	Bone calcification factor
US5399346A (en) *	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
AU5958090A (en)	1989-06-29	1991-01-17	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1
CA2020729A1 (en) *	1989-07-19	1991-01-20	Michael C. Kiefer	Bone morphogenetic protein
US5324519A (en)	1989-07-24	1994-06-28	Atrix Laboratories, Inc.	Biodegradable polymer composition
US5422340A (en) *	1989-09-01	1995-06-06	Ammann; Arthur J.	TGF-βformulation for inducing bone growth
JP3045398B2 (ja) *	1989-09-06	2000-05-29	武田薬品工業株式会社	蛋白質、ｄｎａおよびその用途
US5236456A (en) *	1989-11-09	1993-08-17	Osteotech, Inc.	Osteogenic composition and implant containing same
GB8927546D0 (en) *	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
US5166190A (en)	1990-01-08	1992-11-24	Genentech, Inc.	Method for increasing fertility in males
US5256418A (en)	1990-04-06	1993-10-26	Organogenesis, Inc.	Collagen constructs
US5290271A (en)	1990-05-14	1994-03-01	Jernberg Gary R	Surgical implant and method for controlled release of chemotherapeutic agents
DE69132823T2 (de) *	1990-05-16	2002-07-18	Genetics Institute, Inc.	Knochen- und knorpel-bildung hervorrufende proteine
US5168050A (en) *	1990-05-24	1992-12-01	Genentech, Inc.	Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
US5218090A (en)	1990-06-12	1993-06-08	Warner-Lambert Company	EGF receptor truncates
US5206028A (en)	1991-02-11	1993-04-27	Li Shu Tung	Dense collagen membrane matrices for medical uses
US5208219A (en)	1991-02-14	1993-05-04	Celtrix Pharmaceuticals Inc.	Method for inducing bone growth
US5318898A (en) *	1991-04-02	1994-06-07	Genetics Institute, Inc.	Production of recombinant bone-inducing proteins
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5229495A (en)	1991-06-18	1993-07-20	Ludwig Institute For Cancer Research	Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5216126A (en)	1991-06-19	1993-06-01	Genentech, Inc.	Receptor polypeptides and their production and uses
MX9203083A (es)	1991-06-21	1994-08-31	Genetics Inst	Formulaciones farmaceuticas de proteinas osteogenicas.
KR100255415B1 (ko) *	1991-06-25	2000-05-01	브루스 엠. 에이센	비엠피-9 조성물
US5306307A (en)	1991-07-22	1994-04-26	Calcitek, Inc.	Spinal disk implant
US5171579A (en)	1991-10-11	1992-12-15	Genetics Institute, Inc.	Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
JP3504263B2 (ja) *	1991-11-04	2004-03-08	ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー	組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
WO1993016099A2 (en) *	1992-02-12	1993-08-19	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh	Dna sequences encoding novel growth/differentiation factors
CA2128783C (en)	1992-02-28	2004-10-12	Donald G. Wallace	Injectable ceramic compositions and methods for their preparation and use
WO1993019177A1 (en) *	1992-03-18	1993-09-30	The General Hospital Corporation	FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
CA2153654A1 (en) *	1993-01-12	1994-07-21	Se-Jin Lee	Growth differentiation factor-5
GB9308060D0 (en) *	1993-04-19	1993-06-02	Cancer Res Campaign Tech	Stem cell inhibitor
US5637480A (en) *	1993-05-12	1997-06-10	Genetics Institute, Inc.	DNA molecules encoding bone morphogenetic protein-10
ATE343635T1 (de) *	1993-05-12	2006-11-15	Genetics Inst Llc	Bmp-11 zusammenstellungen
US5447725A (en) *	1993-06-11	1995-09-05	The Procter & Gamble Company	Methods for aiding periodontal tissue regeneration
KR100294026B1 (ko) *	1993-06-24	2001-09-17	야마자끼 순페이	전기광학장치
WO1995001802A1 (en) *	1993-07-09	1995-01-19	The Johns Hopkins University School Of Medicine	Growth differentiation factor-7
US5770444A (en) *	1993-07-09	1998-06-23	The Johns Hopkins University School Of Medicine	Growth differentiation factor-6
AU677866B2 (en) *	1993-08-26	1997-05-08	Board Of Trustees Of The University Of Illinois, The	Neural regeneration using human bone morphogenetic proteins
US5455041A (en) *	1993-09-13	1995-10-03	Research Foundation Of State University Of New York At Buffalo	Method for inducing periodontal tissue regeneration
US6027919A (en) *	1993-12-07	2000-02-22	Genetics Institute, Inc.	BMP-12 and BMP-13 proteins and DNA encoding them
US5399677A (en) *	1993-12-07	1995-03-21	Genetics Institute, Inc.	Mutants of bone morphogenetic proteins
ATE319823T1 (de) *	1993-12-07	2006-03-15	Inst Genetics Llc	Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
US5723331A (en) *	1994-05-05	1998-03-03	Genzyme Corporation	Methods and compositions for the repair of articular cartilage defects in mammals
US5520923A (en) *	1994-09-19	1996-05-28	Genetics Institute, Inc.	Formulations for delivery of osteogenic proteins
US5635372A (en) *	1995-05-18	1997-06-03	Genetics Institute, Inc.	BMP-15 compositions
HU222664B1 (hu) *	1995-06-05	2003-09-29	Genetics Institute, Llc	Csont morfogenetikus protein (BMP) alkalmazása csont és ín vagy szalag funkcionális összeköttetésének regenerálására
US5752974A (en) *	1995-12-18	1998-05-19	Collagen Corporation	Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US6034062A (en) *	1997-03-13	2000-03-07	Genetics Institute, Inc.	Bone morphogenetic protein (BMP)-9 compositions and their uses
IT1302534B1 (it) *	1998-12-21	2000-09-05	Fidia Advanced Biopolymers Srl	Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
US6420243B1 (en) *	2000-12-04	2002-07-16	Motorola, Inc.	Method for producing SOI wafers by delamination

1994
- 1994-12-06 AT AT95904255T patent/ATE319823T1/de active
- 1994-12-06 AU AU13013/95A patent/AU689184B2/en not_active Expired
- 1994-12-06 DE DE69434651T patent/DE69434651T2/de not_active Expired - Lifetime
- 1994-12-06 EP EP95904255A patent/EP0733109B9/de not_active Expired - Lifetime
- 1994-12-06 WO PCT/US1994/014030 patent/WO1995016035A2/en active IP Right Grant
- 1994-12-06 DK DK95904255T patent/DK0733109T3/da active
- 1994-12-06 JP JP51629395A patent/JP3717930B2/ja not_active Expired - Lifetime
- 1994-12-06 CA CA2176942A patent/CA2176942C/en not_active Expired - Lifetime
- 1994-12-06 PT PT95904255T patent/PT733109E/pt unknown
- 1994-12-06 ES ES95904255T patent/ES2255059T3/es not_active Expired - Lifetime
- 1994-12-22 US US08/362,670 patent/US5658882A/en not_active Expired - Lifetime
1996
- 1996-06-04 NO NO19962304A patent/NO317801B1/no not_active IP Right Cessation
- 1996-06-06 FI FI962350A patent/FI119816B/fi not_active IP Right Cessation
- 1996-06-07 OA OA60840A patent/OA10582A/en unknown
1997
- 1997-02-28 US US08/808,324 patent/US6284872B1/en not_active Expired - Lifetime
1999
- 1999-05-26 KR KR1019990019060A patent/KR100353182B1/ko not_active IP Right Cessation
2001
- 2001-08-31 US US09/945,182 patent/US6719968B2/en not_active Expired - Fee Related
2004
- 2004-02-18 US US10/779,635 patent/US6984623B2/en not_active Expired - Fee Related
2005
- 2005-06-08 JP JP2005168624A patent/JP3939729B2/ja not_active Expired - Lifetime
- 2005-06-17 US US11/154,826 patent/US7365052B2/en not_active Expired - Fee Related
2006
- 2006-08-10 JP JP2006218531A patent/JP2007016037A/ja active Pending

Also Published As

Publication number	Publication date
OA10582A (en)	2002-08-23
DE69434651T2 (de)	2007-03-08
DK0733109T3 (da)	2006-07-03
JP3939729B2 (ja)	2007-07-04
FI962350A (fi)	1996-07-16
AU689184B2 (en)	1998-03-26
EP0733109A1 (de)	1996-09-25
EP0733109B1 (de)	2006-03-08
ES2255059T3 (es)	2006-06-16
NO962304D0 (no)	1996-06-04
US7365052B2 (en)	2008-04-29
JP3717930B2 (ja)	2005-11-16
US5658882A (en)	1997-08-19
US20020160494A1 (en)	2002-10-31
US20040146923A1 (en)	2004-07-29
FI962350A0 (fi)	1996-06-06
ATE319823T1 (de)	2006-03-15
EP0733109B9 (de)	2006-07-05
JP2007016037A (ja)	2007-01-25
JP2005312457A (ja)	2005-11-10
DE69434651D1 (de)	2006-05-04
US6719968B2 (en)	2004-04-13
US6984623B2 (en)	2006-01-10
US6284872B1 (en)	2001-09-04
US20070004005A1 (en)	2007-01-04
JPH09506261A (ja)	1997-06-24
NO962304L (no)	1996-06-04
FI119816B (fi)	2009-03-31
CA2176942C (en)	2011-11-01
PT733109E (pt)	2006-07-31
WO1995016035A3 (en)	1995-07-13
CA2176942A1 (en)	1995-06-15
WO1995016035A2 (en)	1995-06-15
KR100353182B1 (ko)	2002-09-28
AU1301395A (en)	1995-06-27

Publication	Publication Date	Title
EP0733109B1 (de)	2006-03-08	Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
EP1690874B1 (de)	2011-05-25	BMP-12, BMP-13 und diese enthaltende Sehnen-induzierende Zusammensetzungen
AU692709B2 (en)	1998-06-11	BMP-15 compositions
EP0592562B1 (de)	1999-01-07	Bmp-9 zusammensetzungen
AU677849B2 (en)	1997-05-08	BMP-10 compositions
US5637480A (en)	1997-06-10	DNA molecules encoding bone morphogenetic protein-10
AU763470B2 (en)	2003-07-24	Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
NO320119B1 (no)	2005-10-31	Benmorfogenetisk protein-11 (BMP-11), DNA-molekyl som koder for dette, samt vektorer og vertceller inneholdende DNA-molekylet og fremgangsmate for fremstilling av BMP-11.
ES2367035T3 (es)	2011-10-27	Bmp-12, bmp-13 y composiciones de las mismas para inducir tendones.
CA2574929C (en)	2011-08-23	Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions

Legal Events

Date	Code	Title	Description
2014-12-15	MK1K	Patent expired